EcoR1 Capital, LLC Buys Galapagos NV, Arcus Biosciences Inc, Protagonist Therapeutics Inc, Sells Relay Therapeutics Inc, Silverback Therapeutics Inc,

• New Purchases: GLPG, PTGX, TNGX, ERAS, IMVT, BLUE, CRBU, VYGR, SRRK,
• Added Positions: RCUS, GRTS, ALEC, RNA, NRIX, DSGN, ODT, STTK, ORIC, ITOS, FLAC, KNTE, FSII, EWTX,
• Reduced Positions: RLAY, SBTX, ACIU, NLTX, ALPN, CRVS, FMTX,
• Sold Out: TBIO, KYMR, ARVN, BCEL, KDNY, ZNTL, BCTG, ALVR, SYRS, MGTA, NGM, CHFW, FSTX,

For the details of EcoR1 Capital, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/ecor1+capital%2C+llc/current-portfolio/portfolio

1. Prothena Corp PLC (PRTA) - 11,284,280 shares, 27.96% of the total portfolio.
2. Morphic Holding Inc (MORF) - 3,951,566 shares, 7.79% of the total portfolio.
3. AnaptysBio Inc (ANAB) - 7,521,024 shares, 7.10% of the total portfolio.
4. Arcus Biosciences Inc (RCUS) - 5,122,359 shares, 6.21% of the total portfolio. Shares added by 53.58%
5. Xencor Inc (XNCR) - 4,906,106 shares, 5.57% of the total portfolio.

EcoR1 Capital, LLC initiated holding in Galapagos NV. The purchase prices were between $52.17 and $70.2, with an estimated average price of $59.52. The stock is now traded at around $52.790000. The impact to a portfolio due to this purchase was 2.85%. The holding were 1,558,749 shares as of 2021-09-30.

EcoR1 Capital, LLC initiated holding in Protagonist Therapeutics Inc. The purchase prices were between $12.95 and $49.69, with an estimated average price of $42.78. The stock is now traded at around $35.740000. The impact to a portfolio due to this purchase was 0.89%. The holding were 1,443,800 shares as of 2021-09-30.

EcoR1 Capital, LLC initiated holding in Tango Therapeutics Inc. The purchase prices were between $9.56 and $17.3, with an estimated average price of $13.13. The stock is now traded at around $13.500000. The impact to a portfolio due to this purchase was 0.58%. The holding were 1,300,000 shares as of 2021-09-30.

EcoR1 Capital, LLC initiated holding in Erasca Inc. The purchase prices were between $17.43 and $24.34, with an estimated average price of $20.69. The stock is now traded at around $18.960000. The impact to a portfolio due to this purchase was 0.52%. The holding were 700,000 shares as of 2021-09-30.

EcoR1 Capital, LLC initiated holding in Immunovant Inc. The purchase prices were between $7.01 and $11.37, with an estimated average price of $9.05. The stock is now traded at around $8.180000. The impact to a portfolio due to this purchase was 0.34%. The holding were 1,140,819 shares as of 2021-09-30.

EcoR1 Capital, LLC initiated holding in bluebird bio Inc. The purchase prices were between $11.24 and $20.99, with an estimated average price of $14.34. The stock is now traded at around $11.480000. The impact to a portfolio due to this purchase was 0.19%. The holding were 802,507 shares as of 2021-09-30.

EcoR1 Capital, LLC added to a holding in Arcus Biosciences Inc by 53.58%. The purchase prices were between $26.93 and $37.68, with an estimated average price of $31.1. The stock is now traded at around $38.070000. The impact to a portfolio due to this purchase was 2.17%. The holding were 5,122,359 shares as of 2021-09-30.

EcoR1 Capital, LLC added to a holding in Gritstone Bio Inc by 62.53%. The purchase prices were between $6.41 and $13.54, with an estimated average price of $9.12. The stock is now traded at around $11.240000. The impact to a portfolio due to this purchase was 0.8%. The holding were 5,560,748 shares as of 2021-09-30.

EcoR1 Capital, LLC added to a holding in Avidity Biosciences Inc by 31.16%. The purchase prices were between $18.16 and $25.21, with an estimated average price of $21.73. The stock is now traded at around $24.690000. The impact to a portfolio due to this purchase was 0.56%. The holding were 2,759,505 shares as of 2021-09-30.

EcoR1 Capital, LLC added to a holding in Nurix Therapeutics Inc by 20.76%. The purchase prices were between $22.71 and $36.69, with an estimated average price of $30.82. The stock is now traded at around $33.920000. The impact to a portfolio due to this purchase was 0.35%. The holding were 2,376,452 shares as of 2021-09-30.

EcoR1 Capital, LLC added to a holding in Design Therapeutics Inc by 47.86%. The purchase prices were between $13.99 and $20.03, with an estimated average price of $16.68. The stock is now traded at around $19.900000. The impact to a portfolio due to this purchase was 0.31%. The holding were 1,863,098 shares as of 2021-09-30.

EcoR1 Capital, LLC added to a holding in Odonate Therapeutics Inc by 348.42%. The purchase prices were between $2.91 and $3.84, with an estimated average price of $3.33. The stock is now traded at around $3.320000. The impact to a portfolio due to this purchase was 0.3%. The holding were 3,727,261 shares as of 2021-09-30.

EcoR1 Capital, LLC sold out a holding in . The sale prices were between $27.64 and $37.85, with an estimated average price of $34.42.

EcoR1 Capital, LLC sold out a holding in Kymera Therapeutics Inc. The sale prices were between $47.8 and $66.66, with an estimated average price of $57.98.

EcoR1 Capital, LLC sold out a holding in Arvinas Inc. The sale prices were between $73.2 and $107.87, with an estimated average price of $88.21.

EcoR1 Capital, LLC sold out a holding in Atreca Inc. The sale prices were between $4.91 and $9.07, with an estimated average price of $6.69.

EcoR1 Capital, LLC sold out a holding in Chinook Therapeutics Inc. The sale prices were between $11.5 and $14.86, with an estimated average price of $13.17.

EcoR1 Capital, LLC sold out a holding in Zentalis Pharmaceuticals Inc. The sale prices were between $46.83 and $73.5, with an estimated average price of $57.7.